New Registration Provisions Will Strengthen Chinese Oversight Of Pharma Industry
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State Food and Drug Administration revised its drug registration provisions July 12, improving supervision and tightening approval standards in the wake of widespread concern related to drug safety